1. Pink Sheet
  2. >>Market Access

What Will USPTO-FDA Collaboration Look Like? Stakeholders To Weigh In On Proposed Initiatives

 
• By Brenda Sandburg

Agencies are holding public ‘listening session’ to get input on method of use patents and ‘skinny labeling,’ REMS patenting, PTAB proceedings and other topics.

FDA and USPTO
USPTO and FDA holding public meeting to get input on areas for collaboration • Source: Nielsen Hobbs; the Pink Sheet|Shutterstock images

The US Patent and Trademark Office and US Food and Drug Administration are working out how they will collaborate to promote greater access to medicines and increase competition. Industry representatives, patients, payors and other stakeholders will get a chance to provide feedback on potential actions the agencies may take to achieve this goal.

The agencies are holding a public “listening session” on 19 January to obtain input on their joint collaboration initiatives. The USPTO announced the meeting in a Federal Register

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

 
• By Sue Sutter

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.